What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows luspatercept reduces transfusion burden in beta-thalassemia major, indicating efficacy over placebo groups.

Luspatercept significantly reduced transfusion burden in beta-thalassemia major patients compared to placebo.
The analysis revealed a 2.22 times higher likelihood of ≥33% transfusion reduction and a 6.22 times likelihood for ≥50% reduction.
Statistical analysis employed included I2 test for heterogeneity and risk of bias assessment via ROBINS-I framework.
Further randomized clinical trials are needed to validate these findings and explore luspatercept's role in clinical practice.

Annaliz Flores-Saldivar (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Systematic review shows luspatercept reduces transfusion burden in beta-thalassemia major, indicating efficacy over placebo groups.

Luspatercept significantly reduced transfusion burden in beta-thalassemia major patients compared to placebo.
The analysis revealed a 2.22 times higher likelihood of ≥33% transfusion reduction and a 6.22 times likelihood for ≥50% reduction.
Statistical analysis employed included I2 test for heterogeneity and risk of bias assessment via ROBINS-I framework.
Further randomized clinical trials are needed to validate these findings and explore luspatercept's role in clinical practice.

Annaliz Flores-Saldivar (2025) studied this question.

View Full Paper

Ask AI

Bookmark